XML 17 R7.htm IDEA: XBRL DOCUMENT v3.4.0.3
Statements of Cash Flows - USD ($)
 9 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Cash flows from operating activities    
Net loss $ (12,882,626) $ (5,567,960)
Stock-based compensation expense 547,109 749,810
Depreciation, amortization and accretion 433,471 73,746
Amortization of debt issuance costs 178,338 0
Amortization of beneficial conversion feature 3,942,613 0
Derivative expense 50,054 0
Amortization of prepaid research and development - related party (Note 11) 91,487 91,488
Deferred taxes 0 (23,910)
Adjustments to reconcile net loss to net cash used in operating activities:    
Decrease (increase) in accounts receivable 72,784 (1,036)
(Increase) in inventory (581,910) (11,233)
(Increase) decrease in prepaid expenses and other (572,238) 496,322
(Increase) in prepaid research and development - related party (Note 11) 0 (150,000)
(Decrease) in accounts payable and accrued liabilities (18,319) (103,158)
(Decrease) in related party payable 0 (392,509)
Increase in accrued compensation 591,451 98,949
Increase (decrease) in interest payable 208,941 (42,673)
Increase in deferred rent 10,560 0
(Decrease) in deferred revenue (64,286) (64,286)
Net cash used in operating activities (7,992,571) (4,846,450)
Cash flows used in investing activities    
Deposits 1,998 (1,998)
Purchases of fixed assets (203,577) 0
Purchase of Primsol business (540,000) 0
Net cash used in investing activities (741,579) (1,998)
Cash flows from financing activities    
Proceeds from convertible note from Ampio converted to stock 0 3,700,000
Proceeds from convertible promissory notes, net (Note 8) 5,175,000 0
Debt issuance costs (Note 8) (298,322) 0
Ampio stock subscription payment 5,000,000 0
Sale of stock subscription 200,000 0
Costs related to the conversion of the convertible promissory notes to equity (29,754) 0
Net cash provided by financing activities 10,046,924 3,700,000
Net change in cash and cash equivalents 1,312,774 (1,148,448)
Cash and cash equivalents at beginning of period 7,353,061 2,639,650
Cash and cash equivalents at end of period 8,665,835 1,491,202
Non-cash transactions:    
Warrant derivative liability related to the issuance of the convertible promissory notes (Note 8) 102,931 0
Primsol business purchase included in primsol payable, $1,250,000 less future accretion of $173,000 1,077,000 0
Conversion of convertible promissory notes and interest of $143,000 to common stock 4,268,000 0
Reclassification of liability based warrants to equity presentation related to the convertible promissory notes 87,000 0
Beneficial conversion feature of $4,943,073 less $3,942,613 of accretion related to unconverted convertible promissory notes 1,001,000 0
Debt issuance costs related to notes that converted to equity $ (183,000) $ 0